Cargando…

Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program

BACKGROUND: Dalfampridine extended-release tablets (dalfampridine-ER; in Europe, prolonged-release fampridine, and elsewhere, fampridine modified or fampridine sustained release), 10 mg twice daily, are available for the treatment of improvement of walking in patients with multiple sclerosis, as dem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crayton, Heidi, Sidovar, Matthew, Wulf, Stanley, Guo, Amy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2014
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445766/ https://www.ncbi.nlm.nih.gov/pubmed/25475652 http://dx.doi.org/10.1007/s40271-014-0102-z

Ejemplares similares

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis
por: Jara, Michele, et al.
Publicado: (2014)

Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients
por: Limone, Brendan L, et al.
Publicado: (2013)

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
por: Hayes, Keith C
Publicado: (2011)

Treatment patterns and health care resource utilization associated with dalfampridine extended release in multiple sclerosis: a retrospective claims database analysis
por: Guo, Amy, et al.
Publicado: (2016)

Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis
por: Jeffery, Douglas R, et al.
Publicado: (2010)

Dalfampridine: Review of its Efficacy in Improving Gait in Patients with Multiple Sclerosis
por: Sahraian, M.A., et al.
Publicado: (2011)

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials
por: Goodman, Andrew D, et al.
Publicado: (2015)

Oral Dalfampridine Improves Standing Balance Detected at Static Posturography in Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2014)

Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis
por: Shi, Jianzhen, et al.
Publicado: (2019)

Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials
por: Zhang, Enyao, et al.
Publicado: (2021)

Mapping the 12-item multiple sclerosis walking scale to the EuroQol 5-dimension index measure in North American multiple sclerosis patients
por: Sidovar, Matthew F, et al.
Publicado: (2013)

Dalfampridine Prior Authorization Program: A Cohort Study
por: Gleason, Patrick P., et al.
Publicado: (2013)

A Massive Overdose of Dalfampridine
por: Fil, Laura J., et al.
Publicado: (2015)

Clarification of Dalfampridine Labeled Indications
por: Rabinowicz, Adrian L., et al.
Publicado: (2012)

Impact of Mobility Impairment on Indirect Costs and Health-Related Quality of Life in Multiple Sclerosis
por: Coleman, Craig I., et al.
Publicado: (2013)

Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States
por: Jara, Michele, et al.
Publicado: (2015)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

Dalfampridine effects on cognition, fatigue, and dexterity
por: Korsen, Melanie, et al.
Publicado: (2016)

The effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: A randomized, double-blind, clinical trial
por: Sadeqi, Yasaman, et al.
Publicado: (2022)

Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol (EQ-5D) health outcomes: an independent validation in a randomized control cohort
por: Sidovar, Matthew F, et al.
Publicado: (2016)

Increasing Patient Safety Among Multiple Sclerosis (MS) Drug Dalfampridine Users by Expanding Awareness of the Serious Side Effects
por: Zaman, Rameez, et al.
Publicado: (2022)

Identification of metabolites of dalfampridine (4-aminopyridine) in dog and rat
por: Caggiano, Anthony, et al.
Publicado: (2013)

Objective and subjective measures of dalfampridine efficacy in clinical practice
por: Klineova, Sylvia, et al.
Publicado: (2018)

Inclusion in limited distribution drug network reduces time to dalfampridine access in patients with multiple sclerosis at a health-system specialty pharmacy
por: Peter, Megan E, et al.
Publicado: (2021)

An exploration of impaired walking dynamics and fatigue in Multiple Sclerosis
por: Burschka, Janina M, et al.
Publicado: (2012)

A double-blind, randomized, controlled study of two dose strengths of dalfampridine extended release on walking deficits in ischemic stroke
por: Page, Stephen J., et al.
Publicado: (2020)

Dalfampridine improves slowed processing speed in multiple sclerosis patients with mild motor disability: post hoc analysis of a randomized controlled trial
por: Pozzilli, Carlo, et al.
Publicado: (2021)

Dalfampridine for Mobility Limitations in People With Multiple Sclerosis May Be Augmented by Physical Therapy: A Non-randomized Two-Group Proof-of-Concept Pilot Study
por: Plummer, Prudence, et al.
Publicado: (2022)

Use of Dalfampridine in a Young Child with Episodic Ataxia Type 2
por: Malamud, Emily, et al.
Publicado: (2022)

Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US
por: Jara, Michele, et al.
Publicado: (2013)

Dalfampridine is associated with de novo occurrence or reoccurrence of positive sensory symptoms in MS
por: Solaro, C., et al.
Publicado: (2015)

Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis
por: Schwartz, Kateryna, et al.
Publicado: (2017)

Patient and Clinician Perspectives of Physical Therapy for Walking Difficulties in Multiple Sclerosis
por: Plummer, Prudence, et al.
Publicado: (2023)

Primary Progressive Multiple Sclerosis: Putting Together the Puzzle
por: Abdelhak, Ahmed, et al.
Publicado: (2017)

Walking impairment in patients with multiple sclerosis: exercise training as a treatment option
por: Motl, Robert W, et al.
Publicado: (2010)

Estimating a minimal clinically important difference for the EuroQol 5-dimension health status index in persons with multiple sclerosis
por: Kohn, Christine G, et al.
Publicado: (2014)

Can optical flow perturbations detect walking balance impairment in people with multiple sclerosis?
por: Selgrade, Brian P., et al.
Publicado: (2020)

Walking together: behavioural signatures of psychological crowds
por: Templeton, Anne, et al.
Publicado: (2018)

Pharmacokinetics of Dalfampridine Extended Release 7.5-mg Tablets in Healthy Subjects and Individuals With Mild and Moderate Renal Impairment: An Open-Label Study
por: Samara, Emil, et al.
Publicado: (2014)

Walking together: women with the severe symptoms of menopause propose a platform for a walking program; outcome from focus groups
por: Sydora, Beate C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_448brpsu0opdt824dqklvn3pnb